Discovery of a new signaling pathway that regulates IOP

Article

Researchers have discovered elevated expression of sFRP1, a WNT signaling inhibitor, in glaucomatous trabecular meshwork (TM) cells. They also observed that the TM has a functional signaling pathway in which elevated sFRP1 decreased outflow facility, according to one researcher.

Researchers have discovered elevated expression of sFRP1 (secreted frizzled related protein), a WNT signaling inhibitor, in glaucomatous trabecular meshwork (TM) cells. They also observed that the TM has a functional signaling pathway in which elevated sFRP1 decreased outflow facility, according to one researcher.

"This validates a new signaling pathway in the TM that regulates IOP," said Abbot F. Clark, senior director of glaucoma research, Alcon Laboratories, Fort Worth, TX.

Gene expression was compared using total RNA isolated from 6 normal and 6 glaucomatous cultured TM cells. After differential gene expression was confirmed, the effect of altered expression on IOP was determined using perfusion cultured human anterior segments and viral expression vector transduction of mouse eyes.

A four- to five-fold increase in the expression of sFRP1 was found in the glaucomatous TM cells. This was confirmed at the protein level.

"We are hypothesizing that sFRP1 blocks WNT signaling, and that leads to an increase in IOP," Dr. Clark said.

An apparent correlation also was found between sFRP1 expression and the signaling mediator beta-catenin. High levels of sFRP1 were associated with low levels of beta-catenin, and the inverse was also observed.

Looking for the effects of this expression, Dr. Clark and colleagues found a statistically significant decrease in outflow facility in perfusion cultured human eyes. Those eyes that received sFRP1 also had lower levels of beta-catenin.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.